Cytotoxic regimen vs no cytotoxic regimen: End‐stage renal disease
Cytotoxic regimen showed no clear difference in end‐stage kidney disease compared with no cytotoxic regimen (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Cytotoxic regimen vs no cytotoxic regimen End‐stage kidney disease · adults and children who have IgA nephropathy proven on renal biopsy Cytotoxic regimen showed no clear difference in end‐stage kidney disease compared with no cytotoxic regimen (low certainty). Immunosuppressive agents for treating IgA nephropathy (2020) · Cochrane Headline outcomes only | RR 0.63 [0.33, 1.2] | 7 studies · 463 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Immunosuppressive agents for treating IgA nephropathy 2020 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.